You can buy Lucidarax at the lowest price at Nextgen.ooo online pharmacy. Daraxonrasib is an oral inhibitor of the RAS GTPase family and a RAS(ON) multi-selective tri-complex inhibitor. On August 26, 2026, it was approved by the FDA for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval established daraxonrasib as a first-in-class targeted therapy directed broadly against active RAS signaling in metastatic pancreatic cancer.
 
RAS proteins are small GTPases that regulate cellular proliferation, differentiation, and survival by cycling between an inactive GDP-bound state and an active GTP-bound state. Oncogenic mutations in RAS, particularly at codons G12, G13, and Q61, can impair normal GTP hydrolysis and promote accumulation of the active RAS(ON) state, resulting in persistent downstream signaling and uncontrolled tumor-cell proliferation. More than 90% of pancreatic ductal adenocarcinomas harbor activating RAS mutations, with KRAS mutations accounting for the majority of these alterations.
 
Daraxonrasib binds to the intracellular chaperone cyclophilin A to form a binary complex that subsequently engages the active, GTP-bound state of mutant and wild-type RAS. Formation of this inhibitory tri-complex blocks the interaction of RAS with downstream effector proteins, including RAF, thereby suppressing RAS-dependent signaling and tumor-cell proliferation. Daraxonrasib can inhibit multiple oncogenic RAS variants rather than a single mutation, providing a broader approach to targeting RAS-driven pancreatic cancer. Clinical efficacy was demonstrated in the Phase 3 RASolute 302 trial, in which daraxonrasib significantly improved overall survival, progression-free survival, and objective response rate compared with standard chemotherapy.